Prevalence of Factor V Leiden Is Not Increased in Women with Recurrent Miscarriage

1 April 1997

journal article
Published by SAGE Publications in Clinical and Applied Thrombosis/hemostasis

Vol. 3 (2) , 137-140
https://doi.org/10.1177/107602969700300213

Abstract

The purpose of this study was to determine if there is an increased prevalence of the thrombophilic genetic mutant factor V Leiden in patients with recurrent miscarriage. Functional assays were conducted for activated protein C resistance and genetic detection of factor V Leiden in 100 women with recurrent miscarriage compared with a control group. The prevalence of factor V Leiden in patients was 6/100 (6%) compared with 3/85 (3.5%) in controls. The difference was not statistically significant. Antithrombotic prophylaxis with heparin and/ or aspirin in a subsequent pregnancy in five of the six patients with factor V Leiden was associated with maintenance of pregnancy and delivery of a live, healthy, full-term infant in four. We have been unable to demonstrate a statistically significant increased prevalence of factor V Leiden in women with recurrent miscarriage. If antithrombotic prophylaxis in pregnancy can be shown by controlled therapeutic trial to prevent miscarriage in these patients, identification of this subgroup would be important. Key Words: Recurrent miscarriage—Factor V Leiden—Activated protein C resistance.

Keywords

This publication has 13 references indexed in Scilit:

Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
The Lancet, 1994
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V
The Lancet, 1994
Activated protein C resistance caused by Arg506Gln mutation in factor Va
The Lancet, 1994
Mutation in blood coagulation factor V associated with resistance to activated protein C
Nature, 1994
Resistance to Activated Protein C as a Basis for Venous Thrombosis
New England Journal of Medicine, 1994
Inherited resistance to activated protein C iscorrected by anticoagulant cofactor activity found to be a property of factorV.
Proceedings of the National Academy of Sciences, 1994
Activated protein C resistance in deep-vein thrombosis
The Lancet, 1994
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects
Blood Coagulation & Fibrinolysis, 1994
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
The Lancet, 1993
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Proceedings of the National Academy of Sciences, 1993